AgomAb Therapeutics NV American Depositary Shares
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases with a focus on chronic fibrotic indications with unmet medical needs. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenos… Read more
Market Cap & Net Worth: AgomAb Therapeutics NV American Depositary Shares (AGMB)
AgomAb Therapeutics NV American Depositary Shares (NASDAQ:AGMB) has a market capitalization of $129.09K ($129.09K) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #40382 globally and #13103 in its home market, demonstrating a -4.99% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying AgomAb Therapeutics NV American Depositary Shares's stock price $13.71 by its total outstanding shares 9416 (9.42K).
AgomAb Therapeutics NV American Depositary Shares Market Cap History: 2026 to 2026
AgomAb Therapeutics NV American Depositary Shares's market capitalization history from 2026 to 2026. Data shows growth from $129.09K to $129.09K (0.00% CAGR).
AgomAb Therapeutics NV American Depositary Shares Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how AgomAb Therapeutics NV American Depositary Shares's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of AGMB by Market Capitalization
Companies near AgomAb Therapeutics NV American Depositary Shares in the global market cap rankings as of March 19, 2026.
Key companies related to AgomAb Therapeutics NV American Depositary Shares by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
AgomAb Therapeutics NV American Depositary Shares Historical Marketcap From 2026 to 2026
Between 2026 and today, AgomAb Therapeutics NV American Depositary Shares's market cap moved from $129.09K to $ 129.09K, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $129.09K | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of AgomAb Therapeutics NV American Depositary Shares was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $129.09K USD |
| MoneyControl | $129.09K USD |
| MarketWatch | $129.09K USD |
| marketcap.company | $129.09K USD |
| Reuters | $129.09K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.